IL304464A - Lipid nanoparticles for targeted delivery of mRNA - Google Patents
Lipid nanoparticles for targeted delivery of mRNAInfo
- Publication number
- IL304464A IL304464A IL304464A IL30446423A IL304464A IL 304464 A IL304464 A IL 304464A IL 304464 A IL304464 A IL 304464A IL 30446423 A IL30446423 A IL 30446423A IL 304464 A IL304464 A IL 304464A
- Authority
- IL
- Israel
- Prior art keywords
- mrna
- targeted delivery
- lipid nanoparticles
- nanoparticles
- lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163138047P | 2021-01-15 | 2021-01-15 | |
| US202163251791P | 2021-10-04 | 2021-10-04 | |
| US202163256811P | 2021-10-18 | 2021-10-18 | |
| PCT/US2022/012786 WO2022155598A2 (en) | 2021-01-15 | 2022-01-18 | Lipid nanoparticles for targeted delivery of mrna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304464A true IL304464A (en) | 2023-09-01 |
Family
ID=82448614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304464A IL304464A (en) | 2021-01-15 | 2023-07-13 | Lipid nanoparticles for targeted delivery of mRNA |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250276086A1 (https=) |
| EP (1) | EP4277603A4 (https=) |
| JP (1) | JP2024504636A (https=) |
| KR (1) | KR20240016244A (https=) |
| AU (1) | AU2022208484A1 (https=) |
| IL (1) | IL304464A (https=) |
| WO (1) | WO2022155598A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117769428A (zh) * | 2021-04-30 | 2024-03-26 | 塔夫茨大学信托人 | 用于治疗疾病和病症的类脂质纳米颗粒 |
| US20250195431A1 (en) * | 2022-03-11 | 2025-06-19 | Trustees Of Tufts College | Lipid nanoparticles for targeted delivery of mrna |
| CN116063245B (zh) * | 2022-12-05 | 2024-09-10 | 南开大学 | 一种中心可降解的mRNA脂质体纳米粒子及其制备方法和应用 |
| WO2024136309A1 (en) * | 2022-12-23 | 2024-06-27 | Green Cross Corporation | Ionizable lipid and use thereof |
| WO2024175550A1 (en) * | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| WO2024178136A1 (en) * | 2023-02-21 | 2024-08-29 | The Brigham And Women’S Hospital, Inc. | Anti-crispr delivery compositions and methods |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025006613A1 (en) * | 2023-06-27 | 2025-01-02 | Hopewell Therapeutics, Inc. | Lipid nanoparticles for cancer immunotherapy |
| WO2025165999A1 (en) * | 2024-01-30 | 2025-08-07 | Trustees Of Tufts College | Lipid nanoparticle for targeted delivery |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2859923T3 (es) * | 2013-02-28 | 2021-10-04 | Univ Tufts | Compuestos de disulfuro para el suministro de agentes farmacéuticos |
| MX2020007944A (es) * | 2018-02-01 | 2020-11-24 | Tufts College | Nanocomplejos similares a los lípidos y sus usos. |
| US20200061211A1 (en) * | 2018-08-22 | 2020-02-27 | Blueallele, Llc | Methods for delivering gene editing reagents to cells within organs |
| JP7691742B2 (ja) * | 2019-06-04 | 2025-06-12 | トラスティーズ オブ タフツ カレッジ | Mrna送達のための合成脂質 |
-
2022
- 2022-01-18 AU AU2022208484A patent/AU2022208484A1/en not_active Abandoned
- 2022-01-18 US US18/272,024 patent/US20250276086A1/en active Pending
- 2022-01-18 JP JP2023542883A patent/JP2024504636A/ja active Pending
- 2022-01-18 KR KR1020237027478A patent/KR20240016244A/ko active Pending
- 2022-01-18 EP EP22740231.0A patent/EP4277603A4/en active Pending
- 2022-01-18 WO PCT/US2022/012786 patent/WO2022155598A2/en not_active Ceased
-
2023
- 2023-07-13 IL IL304464A patent/IL304464A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022155598A3 (en) | 2022-10-20 |
| US20250276086A1 (en) | 2025-09-04 |
| AU2022208484A9 (en) | 2024-07-18 |
| AU2022208484A1 (en) | 2023-08-24 |
| WO2022155598A2 (en) | 2022-07-21 |
| JP2024504636A (ja) | 2024-02-01 |
| EP4277603A4 (en) | 2024-12-18 |
| EP4277603A2 (en) | 2023-11-22 |
| KR20240016244A (ko) | 2024-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304464A (en) | Lipid nanoparticles for targeted delivery of mRNA | |
| SG11202106987WA (en) | Lipids for lipid nanoparticle delivery of active agents | |
| IL266501A (en) | An improved ice-based lipid nanoparticle formulation for mRNA delivery | |
| GB2596224B (en) | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids | |
| GB2600859B (en) | Improved lipid nanoparticles for delivery of nucleic acids | |
| IL282288A (en) | Lipids for the administration of nanoparticulate lipids of active substances | |
| PL4426270T3 (pl) | Nanocząsteczki lipidowe do dostarczania oligonukleotydów | |
| IL312431A (en) | Lipid nanoparticles for delivery of oligonucleotides | |
| ES3063637T3 (en) | Lipid nanoparticle compositions and methods for mrna delivery | |
| AP3284A (en) | Compositions for targeted delivery of SIRNA | |
| EP3399038A3 (en) | Oligonucleotide analogues targeting human lmna | |
| PT4426270T (pt) | Nanopartículas lipídicas para distribuição de oligonucleótidos | |
| CA3288857A1 (en) | Lipid nanoparticles for delivery of agents | |
| HK40015043A (en) | Improved ice-based lipid nanoparticle formulation for delivery of mrna | |
| HK40130986A (zh) | 用於治疗剂的靶向递送的自组装脂质纳米颗粒 | |
| AU2025902189A0 (en) | Lipid Nanoparticles for delivery of aptamers | |
| HK40131620A (en) | Self-assembling lipid nanoparticles for targeted delivery of therapeutic agents | |
| CA3271879A1 (en) | Self-assembling lipid nanoparticles for targeted delivery of therapeutic agents | |
| HK40061037A (en) | Lipids for lipid nanoparticle delivery of active agents | |
| HK1196779A (en) | Lipid nanoparticle compositions and methods for mrna delivery |